Bluebird bio Inc (NASDAQ:BLUE) shares traded 13.75% higher at $1.37 on Wall Street last session.
BLUE stock price is now 8.85% away from the 50-day moving average and -49.58% away from the 200-day moving average. The market capitalization of the company currently stands at $263.09M.
On December 08, 2023, Morgan Stanley Upgraded its previous ‘Underweight’ rating to ‘Equal-Weight’ on the stock increasing its target price from $3 to quote $7, while ‘Cantor Fitzgerald’ rates the stock as ‘Neutral’
In other news, Obenshain Andrew, President and CEO sold 6,095 shares of the company’s stock on Mar 04 ’24. The stock was sold for $9,311 at an average price of $1.53. Upon completion of the transaction, the President and CEO now directly owns 279,998 shares in the company, valued at $0.38 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 04 ’24, Klima Thomas J sold 4,573 shares of the business’s stock. A total of $6,986 was realized by selling the stock at an average price of $1.53. This leaves the insider owning 124,840 shares of the company worth $0.17 million. A total of 1.51% of the company’s stock is owned by insiders.
During the past 12 months, Bluebird bio Inc has had a low of $0.88 and a high of $5.53. As of last week, the company has a debt-to-equity ratio of 1.36, a current ratio of 1.55, and a quick ratio of 1.42. The fifty day moving average price for BLUE is $1.2530 and a two-hundred day moving average price translates $2.6961 for the stock.
The latest earnings results from Bluebird bio Inc (NASDAQ: BLUE) was released for Sep, 2023. According to the Biotechnology Company, earnings per share came in at -$0.66, beating analysts’ expectations of -$0.67 by 0.01. This compares to -$0.94 EPS in the same period last year. The net profit margin was -419.62% and return on equity was -47.81% for BLUE. The company reported revenue of $12.39 million for the quarter, compared to $71000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17353.52 percent. For the current quarter, analysts expect BLUE to generate $16.68M in revenue.
Bluebird bio Inc(BLUE) Company Profile
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company’s clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.
